Details for Patent: 9,034,822
✉ Email this page to a colleague
Which drugs does patent 9,034,822 protect, and when does it expire?
Patent 9,034,822 protects PRADAXA and is included in one NDA.
Protection for PRADAXA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has fifty-two patent family members in forty-two countries.
Summary for Patent: 9,034,822
Title: | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds |
Abstract: | The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants. |
Inventor(s): | Van Ryn; Joanne (Warthausen, DE), Park; John Edward (Warthausen, DE), Hauel; Norbert (Schemmerhofen, DE), Kunz; Ulrich (Biberach an der Riss, DE), Litzenburger; Tobias (Mittelbiberach, DE), Canada; Keith (Southbury, CT), Singh; Sanjaya (Sandy Hook, CT), Waterman; Alisa (Weston, CT) |
Assignee: | Boehringer Igelheim International GmbH (Ingelheim am Rhein, DE) |
Application Number: | 13/916,994 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,034,822
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Boehringer Ingelheim | PRADAXA | dabigatran etexilate mesylate | CAPSULE;ORAL | 022512-001 | Oct 19, 2010 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Boehringer Ingelheim | PRADAXA | dabigatran etexilate mesylate | CAPSULE;ORAL | 022512-003 | Nov 20, 2015 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Boehringer Ingelheim | PRADAXA | dabigatran etexilate mesylate | CAPSULE;ORAL | 022512-002 | Oct 19, 2010 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,034,822
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
10151239 | Jan 20, 2010 |
International Family Members for US Patent 9,034,822
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 079944 | ⤷ Try a Trial | |||
Australia | 2011208719 | ⤷ Try a Trial | |||
Brazil | 112012018021 | ⤷ Try a Trial | |||
Canada | 2787566 | ⤷ Try a Trial | |||
Chile | 2012001927 | ⤷ Try a Trial | |||
China | 102711813 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |